Loading company…
Cambridge, US biotech that was developing therapies for triplet repeat disorders before discontinuing operations in October 2022.
Founded in 2019 and headquartered in Cambridge, US, Triplet Therapeutics, Inc. was developing therapies for genetically driven triplet repeat disorders. Its founder, Nessan Bermingham, has a history of leadership in biotech ventures. In October 2022 the company discontinued its operations after raising USD 29.39 mn in a Series A round led by investors including Alexandria Venture Investments and Pfizer Venture Investments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in